July 22, 2025
Recent safety analyses from the ARANOTE trial emphasized darolutamide’s (Nubeqa) favorable cardiovascular profile compared to other androgen receptor inhibitors (ARIs). Data presented at major oncology congresses in 2025 indicate that darolutamide treatment results in a comparatively lower incidence of significant cardiovascular adverse events. Given cardiovascular safety is a critical consideration in managing older mCSPC patients, these findings support darolutamide’s positioning as a safer option for patients with underlying cardiovascular concerns, potentially influencing clinical decisions in selecting appropriate ARI therapies.
Citation: Oncology Times, April 2025. Available at: https://www.oncologytimes.com/nubeqa-cardiovascular-safety-mcspc
Implication: Superior cardiovascular safety may influence clinicians toward selecting darolutamide, especially in at-risk populations.